Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer

Condition:   Rectal Cancer Intervention:   Sponsors:   Sixth Affiliated Hospital, Sun Yat-sen University;   The Third Affiliated Hospital of Kunming Medical College.;   Sir Run Run Shaw Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Locally Advanced Rectal Cancer Interventions:   Drug: PD-1 antibody;   Drug: Capecitabine;   Drug: Irinotecan;   Radiation: Neoadjuvant Radiotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Incidental perforation remains a significant risk factor for LR, even with optimized management of rectal cancer. This must be considered when discussing adjuvant treatment and follow-up. PMID: 32484249 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
This article will make a further study on this point. Methods: We collected perioperative clinical data from 382 patients with rectal cancer who underwent surgery from September 2015 to May 2017. After 1 month of follow-up, relevant risk factor data were collected and analyzed. Results: Data analysis showed that the incidence of AL was 14.65%. In single factor analysis, patients with high score of NRS-2002, high score of PG-SGA, diabetes, perioperative blood transfusion, postoperative diarrhea, later tumor stage, high score of ASA, low postoperative albumin, and rectal cancer patients with tumor close to the anus...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Discussion: This is the first prospective clinical controlled trial to assess postoperative QoL and efficacy for LRC patients after favorable long-course nCRT. The result is expected to provide new evidence for a more detailed individualized treatment guideline for LRC. Trial registration: This trial was registered at Chinese Clinical Trial Registry (ChiCTR1800017512; ChiCTR.org) on August 2, 2018.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
Conclusion: We suggest a new feasible treatment strategy for the management of synchronous colorectal and prostate cancers.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Authors: Huang Y, Gu X, Ge K, Fu G, Chu J, Wei W Abstract Neoadjuvant chemoradiotherapy has been established as the standard treatment for patients with locally advanced rectal cancer. However, the role of radiotherapy (RT) has not been fully confirmed in advanced colon cancer (LACC). We postulated that patients with pathological T4N2 locally advanced colon cancer would benefit more from RT. 6715 pT4N2M0 colon cancer patients were included in the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoints were 5-year overall survival (OS) and cancer-specific survival (CSS). Propensity score m...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Condition:   Rectum Cancer Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Radiation: intensity modulated radiotherapy;   Procedure: DRE-Endoscopy-MRI-CEA;   Procedure: Nonoperative Management;   Procedure: Local excision;   Procedure: Total Mesorectal Excision;   Behavioral: Quality of Life Questionnai res Sponsor:   Beijing Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hospitals | Neoadjuvant Therapy | Rectal Cancers | Research